Information & Referral

If you have come to our site seeking information, guidance, or referral services for yourself or another person, you have come to the right place. Wellspring is here to provide education and support to those who need assistance confronting the disease of alcoholism and drug dependence.

Information & Referral

Treatment Referrals
Suffering from an addiction problem? We can help you find a treatment facility. You can either browse through our local Treatment Directory, allow us to make suggested referrals by using our self-administered Screening Tool, or if you prefer speaking with one of our professionals, call our confidential Referral Helpline. We are available Monday through Friday from 8 a.m. to 9 p.m. You can also contact us via email at While not intended to diagnose a substance abuse problem, each of these options will help narrow your search for a program that best meets your needs. Note that the options provided do not represent an exhaustive list of all available programs or constitute an endorsement of particular programs. However, these are programs we have worked with and have consistently received positive feedback from those who have accessed their services. If you live outside of Middlesex County New Jersey, you can get help now by calling the New Jersey Addiction Services Hotline anytime at 844-276-2777. You can also access the New Jersey Mental Health Cares Information and Referral Helpline at 1-866-202-HELP (4357).
If you live outside of New Jersey, reach out to the National Council on Alcoholism and Drug Dependence at or 212-269-7797 to find your nearest local resources.
Jason Surks Memorial Resource Center
The Jason Surks Memorial Prevention Resource Center at Wellspring serves as a clearinghouse for free information about alcohol, tobacco and other drugs. Explore our vast collection of online information and helpful links, or visit us at our East Brunswick, NJ location to access free pamphlets, posters and DVD lending library.
More than just a physical and web-based library, our Resource Center is people. If you need assistance planning an educational program, need information for a health fair, or would like to contract with our staff to provide presentations in your community, please call us at 732-254-3344 or send us an email request at

FDA Urges Creation of Generic Abuse-Deterrent Opioid Painkillers


The Food and Drug Administration (FDA) is urging makers of generic drugs to redesign opioid painkillers to make them abuse-deterrent, according to HealthDay.

Medications with abuse-deterrent properties are more difficult to crush or dissolve, making them harder to snort or inject.

If a medication has abuse-deterrent properties, “it does not mean the product is impossible to abuse or that these properties necessarily prevent addiction, overdose or death – notably, the FDA has not approved an opioid product with properties that are expected to deter abuse if the product is swallowed whole,” the agency said in a statement.

“By issuing the draft guidance, the FDA is helping to ensure that generic abuse-deterrent opioids are no less abuse deterrent than their brand-name counterparts,” FDA Commissioner Dr. Robert Califf said. “We hope that the availability of less costly generic products with abuse-deterrent properties has the potential to accelerate the shift away from the older products that do not include abuse-deterrent properties.”

The FDA will also require makers of brand-name opioid painkillers with abuse-deterrent labeling to conduct long-term studies on the effectiveness of the formulas in reducing abuse.

Last week the FDA announced it is requiring immediate-release opioid painkillers to carry a “black box” warning about the risk of misuse, abuse, addiction, overdose and death.

Immediate-release opioids are usually intended for use every four to six hours, while extended-release opioids are generally intended to be taken once or twice a day. According to the FDA, 90 percent of opioid prescriptions are for immediate-release opioids. The FDA placed black-box warnings on extended-release opioids in 2013.Bottles for immediate-release opioids will have a notification stating there is a black-box warning for the drug. Patients will need to go to the manufacturer’s website for details, the article notes.

Pharmacists will be encouraged to give patients a medication guide explaining the risks of the drug.

Log in

fb iconLog in with Facebook
create an account